Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia-Reference-Cited by-同舟云学术

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

Published:2015-01-14 Issue:8 Volume:56 Page:2315-2325
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Rochau Ursula,Sroczynski Gaby,Wolf Dominik,Schmidt Stefan,Jahn Beate,Kluibenschaedl Martina,Conrads-Frank Annette,Stenehjem David,Brixner Diana,Radich Jerald,Gastl Günther,Siebert Uwe

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.982635

Reference59 articles.

1. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

3. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

4. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

5. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia;PharmacoEconomics;2022-09-30

2. Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States;Leukemia & Lymphoma;2021-11-15

3. Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia;Hematologic Malignancies;2021

4. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation;Blood Advances;2019-10-31

5. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia;Applied Health Economics and Health Policy;2019-06-06